In an illustration of Jazz Pharmaceuticals plc’s focus on central nervous system disorders, the company recently presented 13 posters and oral presentations at the American Academy of Neurology annual meeting. The data, which largely buttress already-approved agents, ranged from describing the real-world impact of Xywav (calcium, magnesium, potassium and sodium oxybates) on idiopathic hypersomnia (IH) patients, to the long-term efficacy of its cannabis-derived Epidiolex (cannabidiol) on treatment-resistant epilepsies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?